Neurons and cardiomyocytes derived from induced pluripotent stem cells as a model for mitochondrial defects in Friedreich’s ataxia

Aurore Hick1,2,3,4,5,*, Marie Wattenhofer-Donzé1,2,3,4,5,*, Satyan Chintawar6,*, Philippe Trope1,2,3,4,5, Jodie P Simard8, Nadège Vaucamps1,2,3,4,5, David Gaill9, Laurie Lambot9, Cécile André2,3,4,7, Laurence Reutenaue1,2,3,4,5, Myriam Rai6, Marius Teletin2,3,4,7, Nadia Messaddeq1,2,4,5, Serge N. Schiffmann9, Stéphane Viville2,3,4,7, Christopher E. Pearson6,10, Massimo Pandolfo6,11,§ and Hélène Puccio1,2,3,4,5,§

SUMMARY

Friedreich’s ataxia (FRDA) is a recessive neurodegenerative disorder commonly associated with hypertrophic cardiomyopathy. FRDA is due to expanded GAA repeats within the first intron of the gene encoding frataxin, a conserved mitochondrial protein involved in iron-sulphur cluster biosynthesis. This mutation leads to partial gene silencing and substantial reduction of the frataxin level. To overcome limitations of current cellular models of FRDA, we derived induced pluripotent stem cells (iPSCs) from two FRDA patients and successfully differentiated them into neurons and cardiomyocytes, two affected cell types in FRDA. All FRDA iPSC lines displayed expanded GAA alleles prone to high instability and decreased levels of frataxin, but no biochemical phenotype was observed. Interestingly, both FRDA iPSC-derived neurons and cardiomyocytes exhibited signs of impaired mitochondrial function, with decreased mitochondrial membrane potential and progressive mitochondrial degeneration, respectively. Our data show for the first time that FRDA iPSCs and their neuronal and cardiac derivatives represent promising models for the study of mitochondrial damage and GAA expansion instability in FRDA.

INTRODUCTION

Friedreich’s ataxia (FRDA), the most prevalent hereditary ataxia in Caucasians, is a multisystem autosomal recessive disorder with neurological and cardiac involvement dominating the clinical picture (Pandolfo, 2009). Atrophy of sensory and cerebellar pathways causes ataxia, dysarthria, fixation instability, deep sensory loss and loss of tendon reflexes (Pandolfo, 2009). Cardiac dysfunction leading to congestive heart failure and arrhythmias is the cause of death in 59% of FRDA patients (Tsou et al., 2011). About 10% of FRDA patients develop diabetes, but insulin resistance and β-cell dysfunction are very common (Cnop et al., 2012).

FRDA is caused by reduced expression of the mitochondrial protein, frataxin (Campuzano et al., 1997). Most individuals with FRDA are homozygous for a GAA triplet repeat expansion within the first intron of the frataxin (FXN) gene (Campuzano et al., 1996), which leads to partial silencing of FXN transcription through epigenetic mechanisms (Saveliev et al., 2003). Normal chromosomes contain up to 40 GAA repeats, whereas disease-associated alleles contain 100-1000 GAA repeats (Campuzano et al., 1996). Patients have between 5 and 35% of the frataxin levels in healthy individuals, whereas asymptomatic heterozygous subjects have >50% (Campuzano et al., 1997; Deutsch et al., 2010). The GAA repeat expansions are dynamic and exhibit both intergenerational and somatic instability (De Biase et al., 2007; Monróes et al., 1997). Progressive somatic expansion in a subset of tissues could play an important role in disease progression (Clark et al., 2007). However, the molecular mechanisms underlying GAA repeat instability are currently unknown.

Although the function of frataxin is still under investigation, available evidence supports a role as an activator of iron-sulphur (Fe-S) cluster biogenesis in mitochondria (Schmucker et al., 2011; Tsai and Barondeau, 2010). Fe-S clusters are essential prosthetic groups for many proteins with a variety of functions and subcellular localisations (Lill, 2009; Ye and Rouault, 2010). Frataxin deficiency leads to impairment of Fe-S cluster-containing proteins, altered cellular iron metabolism, mitochondrial dysfunction and increased sensitivity to oxidative stress (Schmucker and Puccio, 2010), but...
The genetic basis of FRDA challenges the development of models, yet required to understand the disease mechanisms and design drug screening assays. The currently available mouse models are either mildly symptomatic (Al-Mahdawi et al., 2006; Miranda et al., 2002) or tissue-specific knockouts (Puccio et al., 2001; Simon et al., 2004). Cellular models include easily obtained, but unaffected cells from FRDA patients, engineered cell lines with frataxin knockdown and cells derived from animal models (Martelli et al., 2012). These models have allowed important advances in understanding frataxin function and pathogenesis, and have been used to test drug effects (Martelli et al., 2012). However, none of them faithfully recapitulates the human disease, and no long-term cultures of mutated vulnerable human cells, such as neurons and cardiomyocytes, are available. Reprogramming of somatic cells to generate pluripotent stem cells (iPSCs) provides a long-term source for deriving any cell type genetically identical to the original somatic cell. Accordingly, iPSCs have been used to obtain cultures of vulnerable cells in genetic diseases (Onder and Daley, 2012). Recently, two groups reported the successful generation of FRDA iPSCs (Ku et al., 2010; Liu et al., 2011). These iPSCs show epigenetic silencing of the FXN locus (Ku et al., 2010), low levels of frataxin expression (Ku et al., 2010; Liu et al., 2011) and GAA repeat instability, with only expansions (Ku et al., 2010) or both expansions and contractions (Liu et al., 2011). Furthermore, one group reports the involvement of mismatch repair (MMR) enzymes in the GAA repeat expansions (Du et al., 2012; Ku et al., 2010). However, none of these studies reported a phenotype resulting from frataxin deficiency in cells obtained from FRDA iPSCs. Here, we describe the generation and characterisation of FRDA iPSCs as well as neurons and cardiomyocytes derived from the FRDA iPSCs. We show that iPSC-derived neurons and cardiomyocytes from FRDA patients maintain GAA repeat expansions of pathological size and express low levels of frataxin compared with control cells, resulting in neuronal and cardiac mitochondrial abnormalities and delayed functional maturation of neurons. Furthermore, we found high levels of GAA instability, both expansions and contractions, in the FRDA iPSCs, which correlates with an upregulation of the MMR enzymes MSH2, MSH3 and MSH6 upon reprogramming. Our findings confirm the mitochondrial pathogenesis of FRDA and provide cellular phenotypes to test potential therapeutics.

**RESULTS**

**Generation and characterisation of iPSC lines from FRDA patient fibroblasts**

Dermal fibroblasts were obtained from two patients with FRDA and two age-matched unrelated healthy individuals after informed consent (see Materials and Methods). Fibroblasts from FRDA patients (FD135 and FD141) had expanded GAA repeats (800/600 and 900/400, respectively) whereas the control fibroblasts (CT136 and CT145) had normal GAA repeats (<20) (Fig. 1A). To obtain iPSCs, the fibroblasts were transduced with lentivirus expressing the reprogramming factors OCT4, SOX2, LIN28 and NANOG as described previously (Lapillonne et al., 2010). At 4–6 weeks after transduction, 5–15 independent iPSC colonies per cell line were manually picked on the basis of their human embryonic stem cell (hESC)-like morphology. The expanded GAA repeats length was determined on each clone prior to full characterisation. All iPSC clones derived from FRDA patients retained pathological GAA repeat expansions, ranging between 400 and 1000 triplets (Fig. 1A), with the exception of one clone, in which one allele contracted to 200 GAA triplets, a size still within the pathological range (FD135-4L clone 28; Fig. 1A).

All iPSC clones stained for the pluripotency markers TRA1-60, TRA1-81 and NANOG (Fig. 1B), most silenced the transduced OCT4, SOX2, NANOG and LIN28 genes and expressed the corresponding endogenous genes (supplementary material Fig. S1A,B). They also showed extensive DNA demethylation at the proximal promoter and the distal enhancer of the endogenous OCT4 locus (supplementary material Fig. S1C), demonstrating

**Clinical issue**

Friedreich’s ataxia (FRDA), an autosomal recessive multisystem disorder characterised by neurodegeneration and cardiomyopathy, is caused by reduced levels of frataxin, an essential mitochondrial protein. Most individuals with FRDA are homozygous for an expanded GAA repeat in the first intron of the frataxin gene (FXN); this leads to repressed FXN expression through epigenetic mechanisms. Animal models of FRDA have enabled substantial progress in understanding pathogenesis, but none fully recapitulates the genetic and epigenetic characteristics of the human disease. Moreover, easily accessible cells from patients do not show any phenotype.

**Implications and future directions**

Patient-derived iPSCs and their derived differentiated cells can be maintained in long-term culture and constitute a permanent source of differentiated cells. These cells are an important resource for research into FRDA pathogenesis and provide an excellent system for testing potential therapeutics, as they fully recapitulate the genetic aspects of the disease and express detectable, measurable phenotypes. The phenotypes characterised in this study for differentiated neurons and cardiomyocytes can be further dissected to identify underlying molecular mechanisms, which appear to involve altered mitochondrial homeostasis. Guiding differentiation toward specific neuronal types that are particularly vulnerable in FRDA (cerebellar deep nuclei and primary sensory neurons) will soon be possible as specific protocols are developed.

**TRANSLATIONAL IMPACT**

**Clinical issue**

The genetic basis of FRDA challenges the development of models, yet required to understand the disease mechanisms and design drug screening assays. The currently available mouse models are either mildly symptomatic (Al-Mahdawi et al., 2006; Miranda et al., 2002) or tissue-specific knockouts (Puccio et al., 2001; Simon et al., 2004). Cellular models include easily obtained, but unaffected cells from FRDA patients, engineered cell lines with frataxin knockdown and cells derived from animal models (Martelli et al., 2012). These models have allowed important advances in understanding frataxin function and pathogenesis, and have been used to test drug effects (Martelli et al., 2012). However, none of them faithfully recapitulates the human disease, and no long-term
faithful reprogramming. In addition, all iPSC clones maintained a normal karyotype. Two or three clones per line were selected for further characterisation (see supplementary material Table S1). Their pluripotency was confirmed in vitro by the formation of embryoid bodies (EBs) that expressed genes from all three embryonic layers (supplementary material Fig. S2). Furthermore, iPSCs were able to form teratomas in SCID mice that contained tissues derived from all three germ layers, including gut-like epithelium (endoderm), cartilage (mesoderm) and neural tissues (ectoderm) (supplementary material Fig. S3). Collectively, these results demonstrate that we successfully generated iPSCs from FRDA fibroblasts with pluripotent propensity.

We next determined whether the expanded GAA repeats in FRDA iPSCs still caused FXN gene silencing present in patient somatic cells (including the fibroblasts used for reprogramming). qRT-PCR analysis confirmed an ~80% decrease in FXN mRNA in all FRDA iPSC clones, as compared with control iPSCs (Fig. 1C). By western blot analysis, FRDA iPSCs had 23% residual frataxin compared with control iPSCs (Fig. 1D), as previously observed in various patient-derived cell lines (Deutsch et al., 2010; Selak et al., 2011). Frataxin deficiency leads to impaired Fe-S cluster biosynthesis and reduced Fe-S cluster enzyme activity in affected tissues (Martelli et al., 2007; Puccio et al., 2001; Rötig et al., 1997). The activity of the Fe-S cluster containing succinate dehydrogenase (SDH) enzyme, the levels of Fe-S dependent proteins, which normally show diminished levels of apoprotein when cells are unable to generate Fe-S clusters (Guillon et al., 2009; Martelli et al., 2007; Navarro-Sastre et al., 2011), and the levels of protein-bound lipoic acid, a cofactor that is synthesised by the Fe-S-containing enzyme lipoic acid synthase (Navarro-Sastre et al., 2011), are not affected in FRDA-derived iPSCs (supplementary material Fig. S4). Together, these results demonstrate that, as for FRDA-derived fibroblasts, despite low levels of frataxin protein in FRDA-derived iPSCs, there is no evidence of Fe-S cluster biogenesis defects.

**iPSC neural differentiation**

In an attempt to generate faithful cell models that recapitulate the pathophysiological features of the disease, we derived human iPSC-derived neurons and cardiomyocytes.
neurons from normal and FRDA iPSCs following an established protocol (Dottori and Pera, 2008) with slight modifications (see Materials and Methods; Fig. 2A). Treatment of iPSCs for 14 days with the bone morphogenetic protein (BMP) antagonist Noggin led to the induction of neural precursors, which were immunopositive for the neuroectodermal markers Nestin and PAX6 (Fig. 2C). Neural precursors were mechanically isolated and cultured in suspension as neurospheres, which extinguished the expression of pluripotent factors NANOG, LIN28 and OCT4 while retaining the expression of SOX2, a transcription factor expressed in neuronal precursors (Fig. 2B). Within 3 days of culture in differentiation conditions, neurospheres started extending processes in all directions. Over 30 days, dense networks of neurons with extended radially projecting neurites positive for the early phase neural marker β-III-tubulin were formed (Fig. 2A). These cells commonly expressed MAP2 (microtubule-associated protein 2), a dendrite specific marker in mature neurons (Fig. 2D,E). Furthermore, synapsin puncta outlining the MAP2-positive neurites became visible by immunostaining (Fig. 2D), evidence of synaptic connections. A subpopulation of neurons expressed the vesicular glutamate transporter 1/2 (VGlut1/2) (Fig. 2E), in accordance with the notion that human neural precursors in the absence of any specific cues mostly generate glutamatergic neurons (Mariani et al., 2012).

**FRDA neurons demonstrate physiological and mitochondrial abnormalities**

To address whether the FRDA iPSC-derived neurospheres and differentiated neurons exhibited any pathological features, we first assessed the GAA expansion and the levels of frataxin expression. Neurospheres and neurons obtained from FRDA iPSCs retained pathological GAA repeat expansions (Fig. 3B) and maintained low FXN mRNA expression levels, at 30-35% of controls (Fig. 3C), but showed no obvious difference in morphology, viability or differentiation potential compared with those derived from control iPSCs (Fig. 3A). However, at 34-39 days of differentiation, 30% less FRDA than control neurons exhibited spontaneous calcium transients (Fig. 2F; supplementary material Movie 1) (Fig. 3D). Patch clamp recordings from neurons participating in spontaneous calcium oscillations showed that 16/28 control cells from two clones displayed voltage-dependent sodium currents, 11 showed repetitive firing during step current injection with little or no accommodation, and five were spontaneously active (Fig. 3D). By contrast, only 6/30 recorded neurons from two FRDA clones displayed voltage-dependent sodium currents, 5 showed repetitive firing during step current injection with little or no accommodation, and one was spontaneously active (Fig. 3D).
dependent sodium currents, four produced only a single action potential during step current injection, and none spontaneously generated action potentials (Fig. 3D). These findings suggest that, contrary to neurons from control iPSCs, neurons from FRDA iPSCs have not yet developed full electrophysiological functionality at 34-39 days of differentiation. However, when allowed additional time for maturation, FRDA iPSC-derived neurons eventually developed similar electrophysiological properties as control neurons. Accordingly, at 54-63 days of differentiation, 5/8 patched FRDA iPSC-derived neurons showed evoked action potentials and 3/8 had also spontaneous repetitive action potentials, similar to findings in control neurons (3/5 showing both evoked and spontaneous repetitive action potentials).

We next estimated mitochondrial integrity and functionality of neurons from FRDA and control iPSCs by assessing their ability to incorporate the mitochondrial membrane-permeable fluorescent dye tetramethylrhodamine methyl ester (TMRM). Flow cytometry analysis of cells

---

**Fig. 3. FRDA neurons are functionally impaired and have reduced mitochondrial membrane potential.** (A) Representative images of iPSC-derived 8-day-old differentiating neurospheres for both control and FRDA clones stained positive for β-tubulin III. (B) PCR analysis of FXN GAA repeat length in iPSCs, neurospheres (NS) and neurons (N) from representative control (CT136-4L clone 38) and FRDA (FD135-4L clone 30 and FD141-4L clone 51) lines. M, molecular weight marker. (C) qRT-PCR analysis of frataxin expression relative to GADPH in control (CT) and FRDA (FD) iPSCs and neurospheres (NS). The value of iPSC CT136-4L clone 25 was arbitrarily set to 100. The data are presented as mean ± s.d. (D) Electrophysiological characteristics of iPSC-derived neurons. Representative traces obtained from current-clamp recordings in maturing iPSC-derived neurons at days 34-39 are shown: (Da) Control neuron (CT 136-4L clone 38) showing spontaneous repetitive action potentials, a recording never detected in any FRDA neurons. (Db) Control neuron (CT 136-4L clone 38) showing repetitive depolarisation-evoked action potentials. (Dc) FRDA neuron (FD141-4L clone 51) showing a single depolarisation-evoked action potential. (Dd) Quantification of iPSC-derived control and FRDA neurons expressing voltage-dependent sodium current, evoked and spontaneous action potentials determined by patch-clamp recording. (De) Quantification of iPSC-derived control and FRDA neurons participating in spontaneous calcium oscillations. (E) Loading of iPSC-derived neurons with the mitochondrial fluorescent dye TMRM. (Ea) Upper panels show representative fluorescent images of FRDA and control neuronal cultures loaded with TMRM. Lower panels show flow cytometry profile with TMRM fluorescence. (Eb) Quantification of mean fluorescence intensity in TMRM-positive cells in R2; **P<0.01, ***P<0.001. (F) Electron microscopy analysis of FRDA iPSCs neurons at 43 days shows no ultrastructural abnormality. Fb is a higher magnification image of the boxed area shown in Fa; n, nucleus; m, mitochondria.
treated with TMRM revealed that FRDA neural cultures at 44-49 days of differentiation had a 40% lower fluorescence than control cultures (Fig. 3E), indicating reduced mitochondrial membrane potential (ΔΨm), which could result from defects in mitochondrial respiratory chain function. Interestingly, ultrastructural analysis of FRDA-derived neurons at the same stage of differentiation showed no defect, in particular mitochondria were well preserved with intact cristae (Fig. 3F).

Differentiation of iPSCs into cardiomyocytes

As the majority of FRDA patients present cardiac defects, we asked whether cardiomyocytes derived from FRDA iPSCs exhibit typical pathophysiological features of the disease. To generate cardiomyocytes, we adapted a protocol to induce differentiation relying on embryoid body (EB) formation combined with a treatment with ascorbic acid, a factor known to promote cardiac differentiation (Takahashi et al., 2003; Wang et al., 2010) (Fig. 4A). The yield of this differentiation protocol varied according to the iPSC line.

Spontaneously beating areas of variable morphology, size and pulse rate emerged around day 20 of differentiation (Fig. 4A; supplementary material Movies 2, 3). Cardiomyocytes at different degrees of maturation coexisted in the same area. qRT-PCR analyses confirmed the expression of cardiac lineage markers, as the transcription factor GATA4; ACTN2 encoding the myofibrillar...
protein actinin α2; \textit{CACNB2} encoding calcium voltage-dependent channel, beta 2 subunit; and \textit{KCQ1} encoding the potassium voltage-gated channel, KQT-like subfamily, member 1 (Fig. 4B; supplementary material Fig. S5). These genes were highly expressed in beating areas compared with adult cardiac mRNAs, reflecting the different degree of maturity. Cardiac troponin T immunostaining showed that the beating areas had comparable structure to heart tissue, with tightly imbricated but not aligned cardiomyocytes (Fig. 4C). Ultrastructural analysis revealed that early cardiomyocytes (<20 days) contained fibres already organised in beams, but only with Z-line drafts (Fig. 4Da). These cells also presented an accumulation of ribosomes and rough endoplasmic reticulum, indicating an intense protein synthesis activity, probably dedicated to building a mature contractile apparatus. With maturation, dense myofibrillar beams formed, with well-organised sarcomeres bounded by straight Z lines (Fig. 4Db). The presence of intercalated disks composed of adherent junctions, gap junctions and desmosomes (Fig. 4Dc) was indicative of an efficient contraction transmission within the beating areas. The majority of cardiomyocytes were mononucleated and a few were binucleated cardiomyocytes as normally observed in human heart (Fig. 4Dd).

FRDA cardiomyocytes recapitulate ultrastructural mitochondrial defects associated with FRDA

Cardiomyocytes derived from FRDA iPSCs retained the pathological GAA repeat expansions, but size heterogeneity was observed (Fig. 5A), possibly because samples from 12-22 beating areas were pooled to obtain sufficient material for genetic analyses. FRDA iPSC-derived cardiomyocytes maintained low levels (36-40%) of frataxin mRNA (Fig. 5A), but higher than in the original iPSCs (Fig. 1C; Fig. 5A), probably reflecting the contribution of beating areas with shorter GAA expansions.

We collected time-lapse images of 273 beating areas from several independent differentiation experiments to detect possible arrhythmias, as can occur in FRDA patients (Tsou et al., 2011). Surprisingly, we observed clonal differences, but no FRDA-related

---

**Fig. 5. FRDA cardiomyocytes present a mitochondrial phenotype.** (A) PCR analysis of \textit{FXN} GAA repeat length in representative pools of beating areas derived from control and FRDA iPSCs (left panel), qRT-PCR analysis of the expression levels of frataxin relative to \textit{GADPH} in the pools of beating areas from control (CT136-4L clone 34) and FRDA (FD141-4L clones 49 and 51) iPSCs (right panel). The value of one pool of beating areas from the control was arbitrarily set to 100. The data are presented as mean ± s.d. **P<0.01, ***P<0.001. (B) Analysis of the beating area contraction profiles by time-lapse imaging. Beating rate (beats per minutes; bpm) distribution (sectors and boxplot) and frequency of arrhythmic events (bars) are shown. The contraction rate distribution is categorised as slow (<60 bpm), intermediate (60-90 bpm) and fast (>90 bpm). (C) Ultrastructural changes in cardiomyocytes derived from FRDA iPSCs. No ultrastructural abnormality was observed in the organisation of the contractile fibre with clear defined sarcomeres. (Ca) Abnormal mitochondrial proliferation and/or accumulation. (Cb,c) Degenerating dark mitochondria with poorly defined cristae, mitochondria with hypertrophic cristae and onion-like mitochondria with coiled cristae. Inset: normal mitochondrion. cc, coiled cristae; dm, cristae; f, contractile fibre; hc, hypertrophic cristae; m, mitochondria; nm, normal mitochondrion.
difference. In particular, even though they were derived from the same FRDA patient (FD141), beating areas from clone 49 had similar rhythmicity as controls, with few arrhythmia events (Fig. 5B), whereas those from clone 51 were slower and more arrhythmic (Fig. 5B). Overall, more than 93% of the recorded arrhythmia events occurred in slow (<60 bpm) beating areas.

Despite the lack of common contractile properties, ultrastructural analyses showed two main types of mitochondrial abnormalities in all seven beating areas from two FRDA iPSC clones: first, a proliferation and/or accumulation of structurally normal mitochondria (Fig. 5Ca; supplementary material Fig. S6); and, second, degenerated mitochondria with a dark matrix and poorly defined, in some cases collapsed cristae (Fig. 5Cb; supplementary material Fig. S6). Such dark mitochondria were found in control cardiomyocytes at a much lower frequency. Additional abnormalities were mitochondria with enrolled or hypertrophic cristae (Fig. 5Cc; supplementary material Fig. S6). These findings parallel the mitochondria damages seen in cardiac tissues from FRDA patients and from FRDA mouse models (Michael et al., 2006; Seznec et al., 2005) and are characteristic for respiration-compromised mitochondria. Mitochondrial pathology first appeared in mature cardiomyocytes within young FRDA beating areas (>1 month), and eventually affected all cardiomyocytes in older beating areas, even the remaining immature ones (supplementary material Fig. S7). No abnormalities in any other organelle were observed.

**Fig. 6.** iPSC show GAA instability over passages and increased expression level of mismatch repair enzymes. (A) PCR analysis of FXN GAA repeat length in fibroblast cell lines (FD135 and CT136) and iPSC clones from control and FRDA iPSCs at different passages (P#). M, molecular weight marker. (B) PCR analysis of FXN GAA repeat length in neurospheres. (C) PCR analysis of FXN GAA repeat length in EBs. (D) qRT-PCR analysis of MSH2, MSH3 and MSH6 expression in fibroblasts (n=8), iPSCs (n=6) and neurospheres (NS; at least 2 weeks of culture, n=7 from four different iPSC clones). No significant difference was seen between control and FRDA iPSC-derived cells. The data are represented as mean ± s.d. ***P<0.005. (E) Western blot analysis of total protein extracts from fibroblasts, iPSCs and neurospheres. Strong bands corresponding to MSH2 and MSH6 are detected in iPSCs and neurospheres; a weak band corresponding to MSH3 is detected in iPSCs and neurospheres (see supplementary material Fig. S8 for longer exposure). Actin was used as a loading control.
GAA repeat instability in FRDA iPSCs

We observed GAA repeat instability upon reprogramming (Fig. 1A), consistent with previous reports of GAA instability in FRDA patient-derived iPSCs (Ku et al., 2010; Liu et al., 2011). Monitoring the expanded GAA repeats in FRDA iPSCs over several passages, we detected both expansions and contractions, whereas normal repeats in control iPSCs remained stable (Fig. 6A). By contrast, during neural differentiation of FRDA iPSCs, only minor differences in GAA repeat length were observed between the starting iPSCs, neurospheres and their neuronal progeny (Fig. 3B), as well as after passaging of the neurospheres up to 65 days in culture (Fig. 6B). These data suggest that repeat instability substantially decreases when iPSCs commit to the neural lineage. This apparent stabilisation of the GAA tract would be consistent with the differentiation-induced stabilisation of CTG instability in myotonic dystrophy type 1 (DM1)-derived hESCs (Seriola et al., 2011). The heterogeneity in GAA repeat sizes in FRDA cardiomyocytes (Fig. 5A) could be a consequence of heterogeneity in the starting iPSC clones or of repeat instability during differentiation. However, GAA repeats were stable during the 6 days of EB differentiation prior to plating (Fig. 6C).

Mismatch repair (MMR) enzymes have previously been reported to be implicated in somatic trinucleotide repeat instability (reviewed by López Castel et al., 2010). In particular, increased levels of the MMR factors MSH2 and MSH3 have been proposed to cause enhanced GAA repeat instability (Ezzatizadeh et al., 2012; Ku et al., 2010). mRNA levels of MMR enzymes MSH2 and MSH6, but not MSH3, markedly increased in iPSCs and in neurospheres compared with the donor fibroblasts (Fig. 6D). No difference was observed between control and FRDA-derived cells, demonstrating that this mRNA upregulation is not related to the FRDA state. Because MMR transcript levels do not always reflect the corresponding protein levels (Chang et al., 2000), MSH2, MSH3 and MSH6 protein levels were assessed. By western blot analysis, the MSH2, MSH3 and MSH6 proteins were not detected in the donor fibroblasts, but abundant levels of MSH2 and MSH6 were detected in both iPSCs and neurospheres (Fig. 6E). MSH3 protein expression remained low in iPSCs and neurospheres, but was detectable compared with fibroblasts (supplementary material Fig. S8). Thus, MSH2, MSH3 and MSH6 proteins are expressed at higher levels in both the undifferentiated iPSCs and neuronal precursors compared with the parental fibroblast cells.

DISCUSSION

In the present study, we report the generation and characterisation of FRDA-derived iPSCs, and their differentiation into neurons and cardiomyocytes. Although the generation of peripheral sensory neurons and spontaneous beating cells using distinct protocols have previously been reported for FRDA-derived iPSC lines (Liu et al., 2011), this is the first report that provides a phenotypic characterisation of the neurons and cardiomyocytes derived from FRDA iPSCs. FRDA iPSCs retained expanded GAA repeats and expressed low levels of frataxin, but they showed no obvious phenotype with respect to control iPSCs. Furthermore, although inter-clonal variation was seen in differentiation efficiency, there was no overall difference in the efficiency or timing of neural and cardiac differentiation between FRDA and control iPSCs, suggesting that a reduced amount of frataxin does not affect the initial commitment to neuronal or cardiac fate. However, we cannot exclude the possibility that differences might emerge if iPSC differentiation is directed towards specific neuronal fates, such as primary sensory neurons, known to be highly vulnerable in FRDA.

Despite their apparently normal differentiation and morphology, young (34–39 days of differentiation) FRDA iPSC-derived neurons showed poor excitability compared with control iPSC-derived neurons (Fig. 3). Older (54–63 days) FRDA iPSC-derived neurons showed essentially normal electrophysiology, suggesting that the differences observed at 34–39 days reflect delayed functional maturation rather than a general functional failure. It is tempting to correlate the delayed maturation with the reduced uptake of TMRM by FRDA iPSC-derived neurons, indicative of reduced mitochondrial membrane potential, which could result from a defect in respiratory chain function rather than proton leak. Such a defect in respiratory chain function could be a direct consequence of Fe-S enzyme deficiency or oxidative stress. However, we cannot exclude the possibility that the differences might be due to loss of sick, non-functional neurons. Importantly, these findings provide measurable parameters to evaluate the effect of potential therapeutics on neurons carrying the FRDA mutations.

Cardiomyocyte physiology did not significantly differ between control and FRDA iPSC-derived cells. Time-lapse analysis of spontaneously contracting beating areas revealed inter-clonal variation rather than a disease-specific phenotype. The beat rates measured in this study were similar to spontaneous rates previously reported (Yazawa et al., 2011). Interestingly, the majority of arrhythmia events occurred in slow beating clusters. As there was heterogeneity in GAA repeat size among the beating clusters, it would be interesting to determine whether the rhythmic abnormalities observed are linked to higher GAA triplet expansions. By contrast, the ultrastructural abnormalities of cardiomyocytes derived from all FRDA iPSCs faithfully recapitulated some features observed in FRDA patients and animal models of the disease (Michael et al., 2006; Seznec et al., 2005). In particular, FRDA iPSC-derived cardiomyocytes present progressive extensive mitochondrial proliferation and accumulate mitochondria with swollen or onion-like cristae and dark mitochondria, which are characteristic of respiration-compromised mitochondria, suggestive of a functional defect in cellular respiration. Conversely, sarcomere disorganisation and mitochondrial iron accumulation, observed both in FRDA patient autopsies and in late stages of the disease in conditional knockout mice (Michael et al., 2006; Seznec et al., 2005), were not apparent in FRDA iPSC-derived cardiomyocytes, suggesting that they recapitulate the very early molecular and cellular changes of FRDA cardiomyopathy.

Neuronal and cardiac dysfunctions develop over several years in FRDA patients or several months in FRDA mouse models; however, both neurons and cardiomyocytes derived from the FRDA iPSCs develop a phenotype suggestive of mitochondrial respiratory chain defect over a relatively short period of time in culture. We cannot exclude the possibility that culture-related stress conditions accelerate the development of FRDA related phenotype in vitro. It is well known that frataxin-deficient cells are vulnerable to stress conditions (Chantrel-Groussard et al., 2001; Jiralerspong et al., 2001; Wong et al., 1999). In any case, our results strongly support impairment of oxidative phosphorylation, which is likely...
to be present as a result of impaired Fe-S cluster biogenesis and possibly oxidative stress, as the main player in FRDA pathogenesis, at least in its early stages. Importantly, our findings provide measurable parameters for evaluating the effect of potential therapeutics on neurons and cardiomyocytes carrying the FRDA mutations.

Similarly to previous reports (Ku et al., 2010; Liu et al., 2011), the expanded GAA repeat showed instability during the reprogramming process. In addition, upon propagation in culture, high instability was observed in all FRDA iPSC clones, yielding both expansions and contractions of the expanded GAA repeats, in contrast with only expansions observed upon passage in culture in previous reports (Du et al., 2012; Ku et al., 2010). This discrepancy correlates with the difference in the GAA repeat size in the reprogrammed fibroblasts. Indeed, in the present report, the sizes of the GAA repeats were 800/600 and 900/400, respectively, whereas the sizes of the repeats in iPSCs showing only repeat expansion with no contraction were 330/380 and 541/420, respectively (Du et al., 2012; Ku et al., 2010). Furthermore, we cannot exclude the possibility that different approaches used to derive iPSCs, such as retroviral transduction and the inclusion of c-Myc in the set of reprogramming factors, and the different culture conditions could play a role. However, although instability during culture passages was not addressed, it is notable that Liu et al., using a similar protocol including the c-Myc transgene in the set of reprogramming factors, observed both expansions and contractions upon reprogramming, with repeat sizes at 527/1058 and 751/1027, respectively (Liu et al., 2011). The repeat instability we observed therefore appears to be more similar to events arising in the somatic tissues of FRDA patients and distinct from the suggested instability in FRDA iPSCs resembling intergenerational expansion (Du et al., 2012; Ku et al., 2010).

Increased expression of the MMR factors is known to be involved in repeat instability (López Castel et al., 2010) and, more specifically, MSH2 and MSH6 have been proposed to promote GAA repeat instability (Du et al., 2012; Ezzatizadeh et al., 2012; Halabi et al., 2012; Ku et al., 2010). Accordingly, we found upregulation of MSH2 and MSH6, and possibly MSH3, in all iPSCs irrespective of their genotype, suggesting an overall activation of mismatch repair during reprogramming. Interestingly, GAA repeats became much more stable in EBs, neurospheres, neurons and possibly cardiomyocytes, even though neurospheres maintained comparable mRNA and protein levels of MSH2 and MSH6 as iPSCs. This suggests that, in addition to MMR, other factors are likely to be involved in GAA repeat instability. The high level of MSH2 and MSH6 in neurospheres contrasts with a very recent report demonstrating that MSH2, MSH3 and MSH6 are expressed at lower levels in neural stem cells than in iPSCs (Du et al., 2012). Although no obvious explanation can explain this discrepancy, we observed high levels of MSH2 and MSH6 in neurospheres derived from three distinct iPSC clones, whereas Du et al. reports results for a unique clone (Du et al., 2012). Limited sample availability precluded MMR expression analysis in neurons and cardiomyocytes; however, previous reports indicate that MMR genes are downregulated and proteins are degraded upon differentiation (Seriola et al., 2011).

In conclusion, we show that iPSCs from FRDA patients maintain expanded GAA repeats and low expression of frataxin, and that iPSC-derived cardiomyocytes and neurons show pathological phenotypes that can be attributed to mitochondrial dysfunction. iPSCs represent a precious resource for studying the pathogenesis of FRDA and testing the effect of potential therapeutics. The major current limitation of this approach is the lack of robust protocols to obtain the most severely affected neuronal types in FRDA, such as large proprioceptive primary sensory neurons and deep cerebellar nuclei projection neurons, but it is reasonable to assume that these will be developed in the future.

MATERIALS AND METHODS

Human iPSC generation and characterisation

Human iPSCs were obtained as previously described (Lapillonne et al., 2010). For more clarity, to distinguish control and FRDA iPSC-derived cells; the original FD136 fibroblasts have been renamed as CT136 and the original iPSC clone FD136-25 as CT136-4L clone 25. Human iPSC characterisation was performed as previously described (Lapillonne et al., 2010). Supplementary material Table S1 gives a summary of the different analyses performed on each iPSC clone.

Molecular analysis

To determine GAA size, genomic DNA was extracted as previously described (Pandolfo, 2006). For the beating areas, DNA and RNA were extracted from the same sample using the RNA XS extraction kit (Macherey Nagels) and the Nucleospin RNA/DNA buffer set extension, according to the manufacturer’s instructions. Beating area pellets were made of 12-22 beating areas, according to their age and size. PCR was performed on 10 ng of genomic DNA using the forward 5′-GGCTTGAACCTCCTCACGGTGT-3′ and reverse 5′-AGGACCACATGCGCCACACTT-3′ primers with the Expand Long Template PCR System Kit (Roche) in 50 μl reaction following the manufacturer’s instructions. Then, 10 μl of the PCR sample was loaded on 1% agarose gel.

RNA was extracted with either TRI Reagent (MRC) or Nucleospin RNA XS (Macherey Nagel) following the manufacturer’s recommendations and treated with Dnase I (Roche Biosciences). cDNA was generated using Superscript II kit (Invitrogen) and oligo-dT. Quantitative RT-PCR (qRT-PCR) was achieved using Light Cycler 480 (Roche Biosciences) with the primers listed in supplementary material Table S2 and, unless indicated, using GAPDH as internal standard. Total RNA from human adult heart tissue (Clontech) was used to evaluate miRNA expression levels in iPSC-derived cardiomyocytes. Beating area pellets were made of 12-22 beating areas, according to their age and size.

Transgene-specific primers were drawn to address reprogramming factor expression (supplementary material Table S2). Each gene-specific forward primer was used in couple with the same reverse primer picked up in IRES sequence immediately in 3′ of ORF. The double ΔCt method was used to quantify transgene expression, with primary human dermal fibroblasts infected with same viruses at MOI 10, as a calibrator. Negative controls were H9 hESC and original fibroblast cells. To avoid monitoring the potential expression of the transgenes, expression of endogenous Oct4, Nanog, Sox2 and Lin 28 was performed using primers designed in the 3′ untranslated region. HuES1 and H9 RNA were kindly provided by Olivier Pourquié (IGBMC, Illkirch, France).
In vitro differentiation analysis
Determination markers were analysed using Taqman Low Density Arrays (Life Technologies) as previously described (Lapillonne et al., 2010).

DNA methylation profile
Genomic DNA purified from H9 human embryonic stem cells, human iPSC and original dermal fibroblasts were bisulphite-treated according to the kit manufacturer (Qiagen). Strand-specific PCR was then performed on POU5F1 promoter according to published protocols and primers (Freberg et al., 2007). After PCR product cloning, between 10 and 15 clones were sequenced to establish DNA methylation profiles.

Teratoma analysis
Human iPSCs clumps were recovered from dishes using collagenase IV and dispase treatment. After washing, every human iPSC line was subcutaneously injected in two SCID mice (750,000 iPSCs per mouse) and teratoma formation followed over 3 months. When tumours reached 1 cm wide, mice were sacrificed, the tumours fixed in 4% PFA and processed for histological analysis.

Neural induction and differentiation
For neural induction, iPSC colonies were treated with Noggin for 14 days as previously described (Dottori and Pera, 2008), then mechanically transferred and cultured in NBN media (neurobasal media A+B27+N2) in the presence of FGF-2 and EGF (both 20 ng/ml; Peprotech, UK), which allowed the formation of neurospheres. Neural precursors were maintained and propagated as neurospheres by the cutting method and by replacing 50% of the medium every 2 days. For neuronal differentiation, neurospheres were plated on laminin-coated glass coverslips in NBN media without proliferating factors. To promote neuronal differentiation, brain-derived neurotrophic factor (BDNF) and neurotrophin 3 (NT3) (both 100 ng/ml; Peprotech, UK) were added in differentiating media. Within 3 days, neurospheres displayed signs of differentiation as they started extending processes in all directions.

Calcium imaging
For calcium dye loading, each coverslip containing differentiating neurospheres was incubated at 37°C for 45 minutes in the presence of 3 μM Oregon Green BAPTA 1 am (Life Technologies, Gent, Belgium) for 30 minutes at 37°C. In this experiment, TMRM was added in the ‘redistribution mode’ to assess ΔΨm, and therefore a reduction in mitochondria-localised TMRM fluorescence represents mitochondrial depolarisation (Abramov et al., 2010). The mean fluorescence intensity was quantified using flow cytometry.

Electrophysiology
Whole-cell patch clamp recordings were performed on individual neurons identified by using infrared differential interference contrast microscopy (Axioskop 2 FS, 63x 0.95w, Zeiss). Recording pipettes were pulled from borosilicate glass capillaries (Hilgenberg, Malsfeld, Germany) on a PiP5 pipette puller (HEKA, Lambrecht-Pfalz, Germany) and presented resistances of 5-8 MΩ when filled with the patch pipette solutions containing the following: 119 mM KMeSO4, 1 mM MgCl2, 0.1 mM CaCl2, 10 mM HEPES, 1 mM EGTA, 12 mM phosphocreatine, 2 mM Na3ATP, 0.7 mM Na2GTP, pH 7.2-7.3 adjusted with KOH, 280-300 mOsm/l. The extracellular solution contained: 126 mM NaCl, 1.6 mM KCl, 2 mM CaCl2, 1 mM MgCl2, 18 mM NaHCO3, 1.2 mM KH2PO4, and 11 mM glucose, equilibrated with 95% O2 and 5% CO2 (pH 7.4). For the recordings, the glass coverslips were transferred into a recording chamber where they were continuously perfused (2-3 ml/min) with the extracellular solution at room temperature. All recordings were made with an Dual EPC10 amplifier and acquired using the software PatchMaster (HEKA). Signals were filtered at 4 kHz using the built-in filter of EPC10 and digitally sampled at 20 kHz. Data were analysed with Igor Pro software (WaveMetrics, Lake Oswego, OR). Passive cellular parameters were extracted in voltage clamp by analysing current relaxation induced by a 10-mV hyperpolarising step from a holding potential of −70 mV.

Measurement of mitochondrial membrane potential
Mitochondrial membrane potential changes (ΔΨm) were detected using the slow, lipophilic, cationic fluorescent redistribution dye tetrakis(methylrhodamine methyl ester) (TMRM). Neurospheres-derived differentiated cells at 6 to 7 weeks old were dissociated by accutase and loaded with 25 nM TMRM (Life Technologies, Gent, Belgium) for 30 minutes at 37°C. In this experiment, TMRM was used in the ‘redistribution mode’ to assess ΔΨm, and therefore a reduction in mitochondria-localised TMRM fluorescence represents mitochondrial depolarisation (Abramov et al., 2010). The mean fluorescence intensity was quantified using flow cytometry. Optimal emission from TMRM lies in the FL2 emission region (573 nm) and mean fluorescence of all test samples was measured with the FACScalibur flow cytometer (BD Biosciences) using the same voltage settings as determined for the negative control.

Cardiac differentiation
For cardiac differentiation, iPSC colonies were harvested after a 30 minutes of treatment with a mix of 1mg/ml collagenase IV (Invitrogen, France) and 2 mg/ml dispase (Invitrogen, France) at 37°C. EBs were formed by culturing small clumps of iPSC colonies in ultra-low attachment plates (Corning, France) for 6 days in DMEM-Ham F12 (1:1) supplemented with 20% KO-serum replacement (KSR), 1% non-essential amino acids, 1% penicillin-streptomycin, 1% glutamax and 0.1 mM 2-mercaptoethanol (all from Gibco, France). EBs were then plated onto 0.1% gelatin-coated plates in the same medium with a progressive replacement of KSR by foetal calf serum (PAA). Cardiac differentiation was
enhanced by adding 100 μM of ascorbic acid (Sigma, France) starting from day 1. First beating areas appeared around day 20 of differentiation.

**Analysis of contraction rhythm in cardiomyocytes**

Images were collected by time lapse every 68 or 26 milliseconds using Metamorph software and converted to multiframe TIFF images. Contraction profiles were built with ImageJ software by assessing the motion of light spots both in space and time. We calculated the ratio of the standard deviation to the mean of the intervals between 20 contractions, as described (Yazawa et al., 2011). The threshold for classifying a beating area as arrhythmic was a ratio at least two times higher than the average ratio of control cells.

**Immunofluorescence**

Full beating areas were rinsed with PBS and fixed in PBS containing 4% paraformaldehyde for 15 minutes at room temperature. Cells were blocked and permeabilised at the same time with PBS (10% NGS, 0.1% BSA, 0.1% Triton X-100) for 2 hours at room temperature. They were then incubated overnight at 4°C with the anti-cTnT primary antibody (1:200; MS-295-P0 from Fisher Scientific) diluted in PBS, 10%NGS, 0.1%BSA, 0.1%Triton X-100. The Alexa Fluor 488 goat anti-mouse secondary antibody (1:1000; Invitrogen) was incubated at room temperature for 1 hour. Immunofluorescence on neurospheres and neurons was performed as previously described (Chintawar et al., 2009). Briefly, to test their ability to express neural stem cell markers, neurospheres were plated on glass coverslips coated with matrigel (BD Biosciences, Erembodegem, Belgium), left overnight and then fixed with 4% paraformaldehyde. Triton X-100-permeabilised cultures were incubated with Nestin and SOX2 (Merck Millipore, Overijse, Belgium) antibodies overnight. For differentiating cultures, β-tubulin-III (Merck Millipore, Overijse, Belgium) and MAP2 (Sigma-Aldrich, Bornem, Belgium) were used as neuronal markers. Synapsin1 and VGlut1/2 (Synaptic Systems, Goettingen, Germany) were used to reveal synapses and vesicular glutamate transporters, respectively. The appropriate secondary antibodies coupled to Cy3 and FITC fluorochromes revealed the signal. In all the cultures, DAPI (4’,6-diamidino-2-phenylindole) was used to counterstain cell nuclei. Slides were mounted using Fluorsave (Calbiochem, Germany). Cultures were visualised either by laser scanning confocal microscope (LSM 510 META) or by Axiosmager Z1 microscope (Zeiss, Jena, Germany). Exported images from LSM and Axiovision software were processed with the ImageJ (NIH) program and exported as TIFF files.

**Immunoblot**

Whole protein extract of human iPSCs were made from frozen pellets by a lysis performed in TGEK-50 buffer (50 mM Tris HCl pH 7.4, 10% glycerol, 1 mM EDTA, 50 mM KCl) with 0.5% Triton X-100 and protease inhibitor (Complete-EDTA-free, Roche). From each sample, 25 μg of protein was electrophoresed in 14% SDS-PAGE and transferred onto nitrocellulose membranes. Primary antibodies (anti-frataxin, 1:250; 18A5DB1, Mitosciences; anti-β-tubulin, 1:40,000; IGBMC-made; anti-SDH (su30kDa), 1:1000; Invitrogen; anti-NDUFS3, 1:2000; Invitrogen; anti-lipoid acid, 1:5000; Calbiochem; and anti-GAPDH, 1:20,000; IGBMC-made) were incubated overnight at 4°C. HRP-conjugated secondary antibody (goat anti-mouse or anti-rabbit, 1:5000; Jackson Immunoresearch) was incubated for 1 hour at room temperature. Immunocomplexes were revealed by SuperSignal West Pico or Dura Chemiluminescent Substrate (37071, Pierce), according to the manufacturer’s instructions.

For mismatch repair protein analysis, cells were resuspended in (0.125 M Tris-HCl pH 6.8, 4% SDS, 10% glycerol) containing Protease Inhibitor Cocktail (Roche) and sonicated for 45 seconds. Protein concentration was determined using the Pierce BCA protein assay kit. Proteins (40 μg) were denatured for 5 minutes at 95°C in 4× loading buffer and resolved by electrophoresis on an 8% polyacrylamide SDS-PAGE gel. Membranes were blocked for 1 hour at room temperature in PBS-T containing 5% (m/v) dried milk. Primary MMR antibodies were incubated simultaneously overnight at 4°C in antibodies anti-MSH2 (1:2800; NA27, Calbiochem), anti-MSH6 (1:2000; 610918, BD Laboratories), anti-MSH3 (1:2000; 611930, BD Laboratories) and anti-Actin Ab-5 (1:20,000; 612656, BD Laboratories). The membranes were incubated for 1 hour in secondary antibody (sheep anti-mouse- HRP, 1:5000; 515-035-062, Jackson Immunoresearch) at room temperature and visualised using ECL plus western blotting detection system (RPN2132, Amersham).

**Enzyme activities**

iPSCs were harvested with collagenase IV and dispase (Invitrogen) in PBS and the dry pellet immediately frozen at −80°C. The activity of the respiratory chain enzyme complex succinate dehydrogenase (SDH, complex II) and the citric acid cycle enzymes isocitrate dehydrogenase (IDH) were determined as previously described (Calmels et al., 2009).

**Electron microscopy**

Cells were fixed in 2.5% paraformaldehyde and 2.5% glutaraldehyde in cacodylate buffer (0.1 M, pH 7.2), rinsed in cacodylate buffer and postfixed in 1% osmium tetroxide in 0.1 M cacodylate buffer for 1 hour at 4°C. Cells were contrasted with uranyl acetate for 2 hours at 4°C, dehydrated, and embedded in Epon. Ultrathin sections were cut at 70 nm and contrasted with uranyl acetate and lead citrate and examined with a Morgagni 268D electron microscope.

**Statistics**

Results are represented as mean ± s.d. Comparisons between groups for mean fluorescence intensity were made using one way analysis of variance (ANOVA) followed by Bonferroni post-hoc test using the Prism Software (GraphPad Software). Histograms were generated using Sigmaplot 10.0. All histograms and images generated using ImageJ software (NIH) were imported in Adobe Illustrator and the final figure was exported in TIFF format. P-values less than 0.05 were considered significant.

**ACKNOWLEDGEMENTS**

We thank Marcel Boeglin, Josiane Hergueux, Laetitia Fuhrman and Jean-Luc Weickert from the IGBMC for technical help. We thank Eric Jeandidier (CHU Mulhouse) for iPSCs carotypes. We thank Karim Hnia, Alain Martelli and Karine Merienne for helpful discussion and reading through the manuscript.

**COMPETING INTERESTS**

The authors declare that they do not have any competing or financial interests.
AUTHOR CONTRIBUTIONS
A.H. designed and performed experiments for iPSC characterisation, differentiation and characterisation of cardiomyocytes from iPSCs. M.W.-D. designed and performed experiments for iPSC derivation and characterisation, neurospheres and neurons from iPSCs. S.C. designed and performed experiments for the differentiation and characterisation of neurospheres and neurons from iPSCs. P.T. designed strategy and performed experiments for iPSCs derivation. J.P.S. performed the mismatch repair western blot. N.V., D.G., L.L., C.A., L.R. and M.R. performed experiments. M.T. was responsible for the teratoma analysis. N.M. was responsible for electron microscopy studies. S.N.S. designed the electrophysiological studies. S.V. designed the iPSC derivation. C.E.P. designed the mismatch repair study. M.P. and H.P. conceived, designed and supervised the complete study. A.H., M.W.-D., S.C. and M.P. wrote the manuscript. All authors read and approved the content of the manuscript.

FUNDING
This work was supported by the US Friedreich's Ataxia Research Alliance (USA) (to H.P. and to M.P.), the Association Française pour l'Ataxie de Friedreich (to H.P.), the Association Française contre les Myopathies (to S.V.), the Ministère de l'économie, de l'industrie et de l'emploi (to S.V.), and the European Community under the European Research Council [grant number 206634/ISCATAXIA to H.P.] and the 7th Framework Program [grant number 242193/EFAPS to H.P. and to M.P.]

SUPPLEMENTARY MATERIAL
Supplementary material for this article is available at http://dmm.biologists.org/lookup/suppl/doi:10.1242/dmm.010900/-/DC1

REFERENCES


Supplementary Information

Induced pluripotent stem cells derived neurons and cardiomyocytes as a model for mitochondrial defects in Friedreich’s ataxia

Hick et al.

Table S1: Summary of different analysis performed on each iPSC clone

<table>
<thead>
<tr>
<th>EXPERIMENTS</th>
<th>CT136-4L</th>
<th>CT145-4L</th>
<th>FD135-4L</th>
<th>FD141-4L</th>
</tr>
</thead>
<tbody>
<tr>
<td>Neuronal phenotypic characterization</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Calcium imaging</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Immunofluorescence βIII-tubulin</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
</tr>
<tr>
<td>Electrophysiology</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
</tr>
<tr>
<td>Mitochondrial membrane potential</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
</tr>
<tr>
<td>Electron microscopy</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
</tr>
<tr>
<td>GAA repeats and FXN mRNA levels</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
</tr>
<tr>
<td>Cardiac phenotypic characterization</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cardiac markers mRNA levels</td>
<td></td>
<td></td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Immunofluorescence cTNT</td>
<td></td>
<td></td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>GAA repeats and FXN mRNA levels</td>
<td>✓</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Electron microscopy</td>
<td>✓</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rhythm analysis</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(GAA)n instability</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>GAA follow-up in iPSCs</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>GAA follow-up in neurospheres</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>GAA follow-up in EBs</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MSH proteins in iPSCs</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MSH proteins in neurospheres</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Application</td>
<td>Gene</td>
<td>Primer sequence</td>
<td></td>
<td></td>
</tr>
<tr>
<td>-------------</td>
<td>---------------</td>
<td>--------------------------</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Normalization</td>
<td>GAPDH forward</td>
<td>TTGCCCTCAACGACCACCTTT</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>GAPDH reverse</td>
<td>TGTTGGTGCCAGGGGTCTTAC</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>β-actin forward</td>
<td>AGACCTGTACGCCAACACAGT</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>β-actin reverse</td>
<td>CGTCAGGGAGGAGCAATGAT</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>18S forward</td>
<td>CGCCGCTAGAGGTGAAATTC</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>18S reverse</td>
<td>CTTCGCTCTGTTCCGTTT</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Transgene</td>
<td>POU5F1 forward</td>
<td>CCTCACTTCACTGCACTGTA</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>SOX2 forward</td>
<td>TGCCGGCGACGCGCATTAACG</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>NANOG forward</td>
<td>TGAGGGCTGCTTGGGAAGCTTGA</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>LIN28 forward</td>
<td>TACCCGTCCTCCGGAGGCACAG</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>IRES reverse</td>
<td>GGAGCGGAAATTGGCCGCCCTA</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ES markers</td>
<td>Oct4 forward</td>
<td>AGTTTGTTGCAGGGTTTGT</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Oct4 reverse</td>
<td>ACTTCACCTTCCCTCCAAACC</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Nanog forward</td>
<td>TTGGGAAGCTGCTTGGGAAG</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Nanog reverse</td>
<td>GATGGGAGGAGGGGAGGAGGA</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Sox2 forward</td>
<td>AGTCTCAAGCGAGGAAAAA</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Sox2 reverse</td>
<td>TTTCAGTGTGCAACTGCTGC</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Lin 28 forward</td>
<td>AGTGGCCTGGATAGGGGAAGT</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Lin 28 reverse</td>
<td>CTTGCATCCCTAGATCTGGT</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cardiac markers</td>
<td>GATA-4 forward</td>
<td>TGGCCTGTTCATCTCACTACG</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>GATA-4 reverse</td>
<td>GGAGAGACGATAGCCCTTGT</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>ACTN2-forward</td>
<td>CACCGTCACCTTCCAATCC</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>ACTN2-reverse</td>
<td>CGCCAGATGTATGGCTTA</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>CACNB2-forward</td>
<td>GCCTACATTAGCCACTTCAA</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>CACNB2-reverse</td>
<td>TTGGGAAGCAGAAAGGATAG</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>KCNQ1-forward</td>
<td>ATGGGAAGCCCTTACTGTT</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>KCNQ1-reverse</td>
<td>AAGCATGTCGGTGAGTGA</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>TBX5-forward</td>
<td>CGTTCTGCACCTAGCTTT</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>TBX5-reverse</td>
<td>TCCTGACTTCTGTCAGTC</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>SerCa2-forward</td>
<td>ACAATGGCGCTCTCTGTTCT</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>SerCa2-reverse</td>
<td>ACATGGAAGCAGATAGGA</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Miscellaneous</td>
<td>Frataxin Forward</td>
<td>AGAGGAAACGCTGGAACCTCTT</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Frataxin reverse</td>
<td>ACGCTTAGGTCCACTTGGATG</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>MSH2 forward</td>
<td>GGAAAAGAAGGATGCAGTCAACA</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>MSH2 reverse</td>
<td>CAAACTGTCAGTGGAAATCC</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>MSH3 forward</td>
<td>GAGTTATGAGTTAATGTTGCC</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>MSH3 reverse</td>
<td>GTCCACCTTCTGCAATCTG</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>MSH6 forward</td>
<td>AGCAAGGCTTGTCAATCTCC</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>MSH6 reverse</td>
<td>CTACAGTTGACCTTCTACTAG</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Figure S1: iPSC repress virus transgenes and *de novo* express endogenous genes in correlation with epigenetic remodelling.

(A) Quantitative RT-PCR analyses of the expression levels of viral SOX2, NANOG, LIN28 and OCT4 relative to GADPH. Data were normalized to LV10 sample. Human ES, original fibroblast cells and derived iPSC were tested. (B) Quantitative RT-PCR analyses of the expression levels of endogenous SOX2, NANOG, LIN28 and OCT4 relative to GADPH on hESC and on original fibroblast cells and derived iPSC normalized to hESC H9. The data are presented as mean ± SD. (C) Methylation status analysis of Oct4 proximal promoter and distal enhancer by bisulfite sequencing. Each line corresponds to a independant sequence. Black dot, methylated C base; White dot, unmethylated C base; Yellow dot, not recovered base.
Figure S2: iPSC-derived embryoid bodies show active expression of differentiation markers from the three germ layers.

For each embryonic layer, 5 representative genes are shown. For a given gene and a given iPSC line, presented result is the activation ratio of transcription in embryoid bodies vs undifferentiated cells.
Figure S3: iPSC pluripotency in vivo
Representative HE stained sections from teratoma, all x10 magnification except: clone 30 ectoderm x20; all clones 51 x15; clone 34 mesoderm x20
**Figure S4: Absence of Fe-S cluster deficit in FRDA iPSCs**

(A) SDH specific activities standardized to isocitrate dehydrogenase (IDH) specific activity. (B) Western blot of whole cell extracts from control or FRDA iPSCs. The mature aconitase (mACO), the intermediate (hFXN 42-210) and mature (hFXN 81-210) forms of frataxin are detected. β-tubulin is used as a loading control. (C) Western blot of whole cell extracts from control or FRDA iPSCs. NUDFS3, SDH, LA-(PDH-E2), LA-(KGDH-E2), the intermediate (hFXN 42-210) and mature (hFXN 81-210) forms of frataxin are detected. β-tubulin and GAPDH are used as a loading control.
Figure S5: Cardiac markers expression in beating areas
Quantitative RT-PCR analyses of cardiac markers expression relative to the 18S housekeeping gene in different pools of beating area from control (CT136-4L clone 34) and patient (FD141-4L clones 49 and 51) iPSCs, normalized to human adult heart. TBX5 transcription factors; calcium-ATPase SerCa2
Figure S6: Additional pictures of ultrastructural changes in cardiomyocytes derived from FRDA iPSCs

a. Abnormal proliferation and/or accumulation of mainly normal mitochondria. b. Onion-like mitochondrion with coiled cristae (cc) and mitochondrion with hypertrophic cristae (hc). c. Dark mitochondrion with poorly defined cristae (dm). Normal mitochondrion (nm), (f) contractile fiber, (n) nucleus.
Figure S7: Mitochondrial status in early versus late immature cardiomyocytes

Early immature cardiomyocytes (< 1 month) from both FRDA and controls display normal mitochondria, with well-defined cristae. At 2 months, both mature and immature cardiomyocytes coexist within the same beating areas. Late immature FRDA cardiomyocytes present similar mitochondrial defect as their neighboring mature cells, as shown by the dark mitochondria (dm). Normal mitochondrion, fibers (f), nucleus (n), lipids (l), reticulum (r).
Figure S8: iPSC show increased expression level of mismatch repair enzymes.

Western blot analysis of total protein extracts from fibroblasts, iPSCs and neurospheres. Strong bands corresponding to MSH2 and MSH6 are detected in iPSCs and neurospheres, while a weak band corresponding to MSH3 is detected in iPSCs and neurospheres. Actin was used as a loading control. Ponceau showing equal loading.